RNA CART19 cells

RNA CART19 cells are a form of chimeric antigen receptor (CAR) T-cell therapy in which a patient's own T cells are genetically modified ex vivo using messenger RNA (mRNA) electroporation to transiently express a CAR targeting the CD19 antigen. Unlike conventional CAR-T therapies that use viral vectors for permanent gene integration, this approach uses mRNA to provide temporary expression of the anti-CD19 CAR. The engineered T cells express tandem signaling domains (TCRζ and 4-1BB), enhancing their ability to recognize and kill CD19-positive cancer cells. This therapy is being investigated primarily for relapsed or refractory Hodgkin lymphoma and other B-cell malignancies[5]. The transient nature of mRNA-based modification may reduce long-term toxicity risks compared to permanently modified CAR-T products.

Other names

non-viral RNA CART19nonviral RNA redirected autologous T cells